Virtual Library

Start Your Search

Wai-Yan Poon



Author of

  • +

    P2.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 965)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.16-22 - Comparing Two Common Radiotherapy Regimens in Non-Small Cell Lung Cancer - A Retrospective Study (ID 13462)

      16:45 - 18:00  |  Author(s): Wai-Yan Poon

      • Abstract
      • Slides

      Background

      In patients with inoperable non-small cell lung cancer (NSCLC), a variety of radiotherapy regimens are used as potentially curative treatments. At the Beatson West of Scotland Cancer Centre (BWoSCC), continuous hyperfractionated accelerated radiotherapy (CHART: 54 Gy in 36 fractions over 12 days) and hypofractionated radiotherapy (55 Gy in 20 fractions over 4 weeks) are the standard fractionations. The aim of this study was to review the clinical outcomes.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      A retrospective study was performed assessing clinical and dosimetric records of all radically treated NSCLC patients at the BWoSCC in 2010 and 2015. We excluded all patients who had received chemotherapy sequentially or concurrently. Patient demographics, tumour characteristics, radiotherapy and survival data were collected and analysed.

      4c3880bb027f159e801041b1021e88e8 Result

      A total of 254 patients received radical radiotherapy: 113 were treated in 2010 (52 CHART and 61 with 55/20); 141 were treated in 2015 (43 CHART and 98 with 55/20).

      Median age for CHART patients was 76 IQR (70-81), and for 55/20 patients 74 (68-79).

      Overall, CHART patients had poorer performance status (PS). 32% of CHART patients had a PS 2/3 compared to 19.5% of 55/20 patients (p<0.01). In 2010, 68% of CHART patients were PS 0/1 and 32% were PS 2/3. In 2015, 53% were PS 0/1 and 47% were PS 2 (p<0.01).

      In 2010, more CHART patients had unknown staging compared with the 55/20 patients (28% versus 4%). By 2015, there was no statistically significant difference.

      The max planning target volumes (PTV) were on average larger in 2015 than 2010. The PTV of CHART patients increased by 19.8%. The PTV of the 55/20 patients increased by 3.4%.

      Median progression free survival (progression or death) was 14.3 months 95%CI (11.0 to 18.0) for 55/20 patients and 14.6 months 95%CI (11.0 to 18.7) for CHART patients. Median overall survival was 23.2 months 95%CI (16.2 to 30.2) for 55/20 patients and 22.2 months 95%CI (14.5 to 29.2) for CHART patients.

      8eea62084ca7e541d918e823422bd82e Conclusion

      In this single centre study, we present a series of patients treated with 2 different radical radiotherapy regimens. Despite PTV volumes on average increasing from 2010 to 2015, the median survival has decreased for CHART. In our centre we introduced Stereotactic ablative radiotherapy as a new option for patients with stage I and II disease. Many patients who previously received CHART or 55/20 will now be eligible for SABR. It may be that this has changed selection criteria, with more advanced patients being put forward for CHART.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.